Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Loxo Oncology at Lilly Announces Details of LOXO-305 Presentations at the 2020 American Society of Hematology (ASH) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Loxo Oncology at Lilly Announces Updated Data from the Phase 1\/2 BRUIN Clinical Trial for LOXO-305","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Presents New Data on Retevmo in Advanced RET Fusion-Positive Gastrointestinal and Other Cancers at 2021 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Foghorn Therapeutics","pharmaFlowCategory":"D","amount":"$380.0 million","upfrontCash":"$300.0 million","newsHeadline":"Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn\u2019s Proprietary Gene Traffic Control\u00ae Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform"}]

    Find Clinical Drug Pipeline Developments & Deals by Loxo Oncology Inc

    Menu

    Loxo Oncology Inc

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Loxo Oncology Inc

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn’s Proprietary Gene Traffic Control® Platform

              Details:

              The collaboration includes co-development and co-commercialization agreement for Foghorn’s selective BRM oncology program and undisclosed oncology target. The collaboration includes three additional discovery programs using Foghorn’s proprietary Gene Traffic Control platform.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Small molecule

              Recipient: Foghorn Therapeutics

              Deal Size: $380.0 million Upfront Cash: $300.0 million

              Deal Type: Collaboration December 13, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Loxo Oncology Inc

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lilly Presents New Data on Retevmo in Advanced RET Fusion-Positive Gastrointestinal and Other Cancers at 2021 AACR Annual Meeting

              Details:

              First-time data from the Phase I/II LIBRETTO-001 trial of Retevmo (selpercatinib) treatment showed promising antitumour activity and safety in various RET fusion-positive advanced solid tumours. Safety consistent with known profile of Retevmo.

              Lead Product(s): Selpercatinib

              Therapeutic Area: Oncology Product Name: Retevmo

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Recipient: Eli Lilly

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 11, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Loxo Oncology Inc

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305

              Details:

              In the 121 efficacy-evaluable BTK-pretreated patients, the ORR was 62%. This deepening of response over time is consistent with other BTK inhibitors and suggests the overall efficacy profile of LOXO-305 will continue to strengthen with additional follow-up.

              Lead Product(s): Loxo-305

              Therapeutic Area: Oncology Product Name: LOXO-305

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Eli Lilly

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 07, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Loxo Oncology Inc

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Loxo Oncology at Lilly Announces Details of LOXO-305 Presentations at the 2020 American Society of Hematology (ASH) Annual Meeting

              Details:

              LOXO-305 oral presentations will provide updated data from the ongoing Phase 1/2 BRUIN clinical trial in previously treated chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma, Waldenström's macroglobulinemia, and other non-Hodgkin lymphomas.

              Lead Product(s): Loxo-305,Venetoclax,Rituximab

              Therapeutic Area: Oncology Product Name: LOXO-305

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 05, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY